165 related articles for article (PubMed ID: 33108504)
21. Electrocardiographic Characterization of Ramucirumab on the Corrected QT Interval in a Phase II Study of Patients With Advanced Solid Tumors.
Olszanski AJ; Smith DC; Camacho LH; Thompson J; Ramalingam SS; Harvey RD; Campos L; Ferry D; Tang S; Gao L; Safran H
Oncologist; 2016 Apr; 21(4):402-3. PubMed ID: 26984445
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of the potential for QTc prolongation with avelumab.
Vugmeyster Y; Güzel G; Hennessy M; Loos AH; Dai H
Cancer Chemother Pharmacol; 2019 Nov; 84(5):1017-1026. PubMed ID: 31478078
[TBL] [Abstract][Full Text] [Related]
23. Exposure-response modeling of the effect of glasdegib on cardiac repolarization in patients with cancer.
Fostvedt LK; Shaik N; Martinelli G; Wagner AJ; Ruiz-Garcia A
Expert Rev Clin Pharmacol; 2021 Jul; 14(7):927-935. PubMed ID: 33993815
[TBL] [Abstract][Full Text] [Related]
24. Pharmacokinetics and Safety of Lurbinectedin Administrated with Itraconazole in Cancer Patients: A Drug-Drug Interaction Study.
Moreno I; Hernández T; Calvo E; Fudio S; Kahatt C; Martínez S; Iglesias JL; Calafati RO; Pérez-Ramos L; Montilla L; Zeaiter A; Lubomirov R
Mar Drugs; 2024 Apr; 22(4):. PubMed ID: 38667795
[TBL] [Abstract][Full Text] [Related]
25. Assessment of the effect of erdafitinib on cardiac safety: analysis of ECGs and exposure-QTc in patients with advanced or refractory solid tumors.
Valade E; Dosne AG; Xie H; Kleiman R; Li LY; Perez-Ruixo JJ; Ouellet D
Cancer Chemother Pharmacol; 2019 Sep; 84(3):621-633. PubMed ID: 31280362
[TBL] [Abstract][Full Text] [Related]
26. Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial.
Trigo J; Subbiah V; Besse B; Moreno V; López R; Sala MA; Peters S; Ponce S; Fernández C; Alfaro V; Gómez J; Kahatt C; Zeaiter A; Zaman K; Boni V; Arrondeau J; Martínez M; Delord JP; Awada A; Kristeleit R; Olmedo ME; Wannesson L; Valdivia J; Rubio MJ; Anton A; Sarantopoulos J; Chawla SP; Mosquera-Martinez J; D'Arcangelo M; Santoro A; Villalobos VM; Sands J; Paz-Ares L
Lancet Oncol; 2020 May; 21(5):645-654. PubMed ID: 32224306
[TBL] [Abstract][Full Text] [Related]
27. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
28. Onartuzumab with or without bevacizumab in combination with weekly paclitaxel does not prolong QTc or adversely affect other ECG parameters in patients with locally recurrent or metastatic triple-negative breast cancer.
Borin MT; Chen M; Mocci S; Rubets I; Chittenden J; Aldairy W; Stroh M
Cancer Chemother Pharmacol; 2015 Feb; 75(2):401-10. PubMed ID: 25542267
[TBL] [Abstract][Full Text] [Related]
29. Doxorubicin plus lurbinectedin in patients with advanced endometrial cancer: results from an expanded phase I study.
Kristeleit R; Moreno V; Boni V; Guerra EM; Kahatt C; Romero I; Calvo E; Basté N; López-Vilariño JA; Siguero M; Alfaro V; Zeaiter A; Forster M
Int J Gynecol Cancer; 2021 Nov; 31(11):1428-1436. PubMed ID: 34610971
[TBL] [Abstract][Full Text] [Related]
30. Adavosertib (AZD1775) does not prolong the QTc interval in patients with advanced solid tumors: a phase I open-label study.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Rekić D; Dota C; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Aug; 92(2):141-150. PubMed ID: 37368100
[TBL] [Abstract][Full Text] [Related]
31. Differentiating the Effect of an Opioid Agonist on Cardiac Repolarization From µ-Receptor-mediated, Indirect Effects on the QT Interval: A Randomized, 3-way Crossover Study in Healthy Subjects.
Darpo B; Zhou M; Bai SA; Ferber G; Xiang Q; Finn A
Clin Ther; 2016 Feb; 38(2):315-26. PubMed ID: 26749217
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of the potential effect of dacomitinib, an EGFR tyrosine kinase inhibitor, on ECG parameters in patients with advanced non-small cell lung cancer.
Tan W; Giri N; Quinn S; Wilner K; Parivar K
Invest New Drugs; 2020 Jun; 38(3):874-884. PubMed ID: 31858327
[TBL] [Abstract][Full Text] [Related]
33. Phase I study to assess the pharmacokinetics and the effect on cardiac repolarization of amrubicin and amrubicinol in patients with advanced solid tumors.
Chen N; Chawla SP; Chiorean EG; Read WL; Gorbaty M; Mita AC; Yung L; Bryan P; McNally R; Renschler MF; Sharma S
Cancer Chemother Pharmacol; 2013 Apr; 71(4):1083-94. PubMed ID: 23400695
[TBL] [Abstract][Full Text] [Related]
34. A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Lush RM; Patnaik A; Sullivan D; Papadopoulos KP; Trucksis M; McCrea J; Cerchio K; Li X; Stroh M; Selverian D; Orford K; Ebbinghaus S; Agrawal N; Iwamoto M; Wagner JA; Tolcher A
Cancer Chemother Pharmacol; 2012 Oct; 70(4):567-74. PubMed ID: 22878520
[TBL] [Abstract][Full Text] [Related]
35. Safety and tolerability of lurbinectedin (PM01183) in patients with acute myeloid leukemia and myelodysplastic syndrome.
Benton CB; Chien KS; Tefferi A; Rodriguez J; Ravandi F; Daver N; Jabbour E; Jain N; Alvarado Y; Kwari M; Pierce S; Maiti A; Hornbaker M; Santos MA; Martinez S; Siguero M; Zblewski D; Al-Kali A; Hogan WJ; Kantarjian H; Pardanani A; Garcia-Manero G
Hematol Oncol; 2019 Feb; 37(1):96-102. PubMed ID: 30153704
[TBL] [Abstract][Full Text] [Related]
36. Olaparib does not cause clinically relevant QT/QTc interval prolongation in patients with advanced solid tumours: results from two phase I studies.
Swaisland H; Plummer R; So K; Garnett S; Bannister W; Fabre MA; Dota C; Fielding A
Cancer Chemother Pharmacol; 2016 Oct; 78(4):775-84. PubMed ID: 27553432
[TBL] [Abstract][Full Text] [Related]
37. Effect of Pevonedistat, an Investigational NEDD8-Activating Enzyme Inhibitor, on the QTc Interval in Patients With Advanced Solid Tumors.
Zhou X; Richardson DL; Dowlati A; Goel S; Sahebjam S; Strauss J; Chawla S; Wang D; Mould DR; Samnotra V; Faller DV; Venkatakrishnan K; Gupta N
Clin Pharmacol Drug Dev; 2023 Mar; 12(3):257-266. PubMed ID: 36382849
[TBL] [Abstract][Full Text] [Related]
38. Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers.
Wang Z; Grasela DM; Krishna G
Clin Ther; 2007 Jun; 29(6):1098-106. PubMed ID: 17692724
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study.
Xu N; Redfern CH; Gordon M; Eppler S; Lum BL; Trudeau C
Cancer Chemother Pharmacol; 2014 Dec; 74(6):1251-60. PubMed ID: 25344761
[TBL] [Abstract][Full Text] [Related]
40. A Phase I cardiac safety and pharmacokinetic study of tivozanib hydrochloride in patients with advanced solid tumors.
Moore K; Infante JR; Cotreau MM; Wilson L; Strahs AL; Vargo DL; Chadha M
Clin Pharmacol Drug Dev; 2014 Jul; 3(4):284-9. PubMed ID: 27128834
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]